ARPA-H Runs Its Small-Business Program Like A Venture Pitch, Not A Grant Cycle. The First Gate — A Solution Summary — Closes July 10, And It Decides Everything That Follows.

The Advanced Research Projects Agency for Health was built to be the un-NIH — a high-risk, high-reward agency modeled on DARPA, designed to fund the breakthroughs the conventional biomedical-research system is too cautious or too slow to back. Its small-business program reflects that DNA. ARPA-H's FY2026 SBIR/STTR solicitation does not work like a traditional grant competition with a single fat application and a study-section score. It works like a venture pitch: a short written gate first, an oral presentation second, and funding instruments structured as contracts rather than grants. For small health-tech companies used to the NIH rhythm, that difference is the whole story — and the first gate is closer than it looks.

The headline date is the Solution Summary, due July 10, 2026 at 11:59 AM ET. That short document is the entire basis on which ARPA-H decides whether to invite a company to the next round. Companies that are invited then submit a Technical Oral Presentation (a "Pitch"), a Cost Proposal, and a Task Description Document by September 9, 2026. Awards take the form of contracts of up to $600,000 for Phase I and up to $3.5 million for Phase II, and the program supports Phase I, Direct-to-Phase-II, and Fast Track pathways across seven topic areas spanning women's health, advanced materials, diagnostics, autoimmune disease, toxin removal, therapeutic development, and neurosurgical robotics.

The two-step process inverts where the work goes

In a conventional NIH SBIR application, the heavy lifting is front-loaded: you write a full, detailed proposal, submit it, and wait. ARPA-H splits that effort across two gates, and the strategic implication is significant. The Solution Summary is short by design — it is a screening instrument, not the proposal. Its job is to convince ARPA-H that your idea is bold enough, feasible enough, and aligned enough with a topic area to be worth a deeper look. Companies that pour a full proposal's worth of detail into the Solution Summary are misreading the assignment; companies that treat it as a throwaway abstract are squandering their only shot at the gate.

The right posture is to treat the Solution Summary as a pitch deck in prose: a crisp articulation of the problem, why current approaches fall short, what your specific solution is, why it is credible, and why it fits the ARPA-H mold of transformational rather than incremental. The detailed cost and technical work comes only if you are invited — at the Technical Oral Presentation stage in September. That sequencing is a gift to small teams with limited proposal-writing bandwidth: you don't build the full package until ARPA-H has signaled real interest. But it raises the stakes on the summary, because a weak first gate means you never get to make the deeper case at all.

"Transformational, not incremental" is a real screen

ARPA-H's framing — its tagline leans on the idea that "the status quo isn't working" — is not marketing fluff; it is an actual evaluation lens. The agency exists to fund things that move health outcomes by leaps, not percentages. A Solution Summary that promises a modest improvement on an existing diagnostic, a slightly better material, or an incremental therapeutic refinement is competing in the wrong agency. NIH SBIR rewards rigorous, well-powered, lower-risk development. ARPA-H rewards ambition with a credible path — the kind of project that, if it works, changes a standard of care or creates a capability that didn't exist.

The hard part is holding both halves of that standard at once. Pure ambition with no feasibility reads as a pipe dream; pure feasibility with no ambition reads as something NIH should fund instead. The companies that clear ARPA-H's bar tend to articulate a genuinely transformational goal and a concrete, milestone-driven path to a first proof point that fits within a Phase I or Direct-to-Phase-II budget and timeline.

Direct-to-Phase-II and Fast Track are the leverage points

The pathway you choose matters as much as the science. ARPA-H offers three:

• Phase I — the traditional feasibility stage, up to $600K, for ideas that need to prove their core premise.
• Direct-to-Phase-II — skips Phase I entirely for companies that can document they have already completed equivalent feasibility work, jumping straight to the up-to-$3.5M development stage.
• Fast Track — combines the phases for a smoother, faster transition.

For a company that already has feasibility data — from prior funding, internal R&D, or earlier work — Direct-to-Phase-II is the highest-leverage option in the program. It compresses what would otherwise be a multi-year, two-award sequence into a single larger award, and it signals to ARPA-H that you are past the science-experiment stage and into building something deployable. The catch is documentation: you must convincingly establish that the Phase I-equivalent work is genuinely done. Companies sitting on completed feasibility work who default to a Phase I application out of habit are leaving both money and time on the table.

Eligibility is standard SBIR — with ARPA-H's domestic emphasis

The eligibility rules track the federal SBIR baseline, which the program's 2026 reauthorization reaffirmed and tightened. Proposers must be small businesses with no more than 500 employees, with majority ownership by U.S. citizens or another U.S.-based small business, and all work performed in the United States. That domestic-performance requirement is not boilerplate in 2026 — federal health and defense programs alike have sharpened foreign-risk screening this year, and ARPA-H's structure reflects the broader push to keep sensitive health innovation onshore. Companies with offshore development arrangements or significant foreign ownership need to resolve those questions before investing in a Solution Summary.

The clock, and the homework

ARPA-H ran a Small Business Program Proposers' Day on June 11, 2026, where agency leaders walked through the solicitation, the application and contracting process, and the seven topic areas. If you missed it, the recorded materials and the topic descriptions are essential homework — ARPA-H's topic areas are specific, and a Solution Summary that doesn't map tightly to a named topic's intent is unlikely to clear the gate. (Note that ARPA-H released this as a draft solicitation in its run-up; confirm the final solicitation terms and any date adjustments on the official ARPA-H portal before submitting.)

With the Solution Summary due July 10, the practical sequence for an interested company is tight but manageable:

1. Map your idea to a specific topic area — and if it doesn't fit one cleanly, reconsider whether ARPA-H is the right venue rather than forcing it.
2. Decide your pathway honestly — if you have documented feasibility work, build toward Direct-to-Phase-II; if not, Phase I.
3. Write the Solution Summary as a pitch, not a proposal — problem, gap, solution, credibility, transformational upside, in that order.
4. Confirm eligibility and domestic-performance before you invest — ownership, employee count, and U.S.-work requirements are pass/fail.
5. Pre-stage the September package mentally — know what your cost proposal and task description would look like, so an invitation doesn't catch you flat-footed.

ARPA-H is one of the few corners of the 2026 federal landscape explicitly built to fund the audacious — and its small-business program offers contracts large enough to matter to an early-stage health company. But it rewards a fundamentally different muscle than NIH does: the ability to pitch a bold idea concisely and then deliver a credible plan on a short clock. The July 10 Solution Summary is where that muscle gets tested first. Everything else in the process depends on clearing it.

Granted helps health-tech startups and small businesses find and win non-dilutive federal funding. Explore SBIR and ARPA-H opportunities or run a personalized search to see which topics fit your technology.